Neuromedin N: natural brain peptide related to neurotensin
A naturally occurring peptide found in the brain and spinal cord that activates the neurotensin receptor, influencing pain suppression and dopamine signaling; used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Neuromedin N is a naturally occurring six-amino-acid peptide found in the brain, spinal cord, and peripheral tissues of mammals. It is closely related to neurotensin — the larger neuropeptide it was discovered alongside — and activates the same primary receptor, neurotensin receptor type 1 (NTSR1). Neuromedin N was first isolated from porcine spinal cord in 1984 by Minamino and colleagues, who identified it through a bioassay for smooth-muscle contracting activity and determined its sequence to be Lys-Ile-Pro-Tyr-Ile-Leu (KIPYIL) — sharing the four C-terminal residues with neurotensin (Minamino et al., Biochemical and Biophysical Research Communications, 1984). It is produced and released in many of the same tissues as neurotensin, and is distributed across human, mouse, rat, bovine, porcine, canine, and related mammalian species.
History
Neuromedin N was identified as part of a systematic search for novel neuropeptides in porcine spinal cord extracts in the early 1980s, using a guinea pig ileum contraction bioassay. Minamino and colleagues (1984) isolated the hexapeptide, sequenced it by microsequencing, and confirmed the structure by chemical synthesis. The same year, the neurotensin precursor gene was shown to encode both neurotensin and neuromedin N within the same pro-peptide — establishing that the two peptides are co-products of a single gene, now called the pro-neurotensin/neuromedin N (pro-NT/NMN) precursor. Kitabgi (Journal of Molecular Medicine, 2006) later showed that prohormone convertases — members of the PC family including PC1, PC2, and PC7 — process this precursor in tissue-specific and cell-line-specific patterns, generating neurotensin and neuromedin N in different ratios depending on context. The structural underpinnings of how these endogenous ligands engage NTSR1 were illuminated by White and colleagues (Nature, 2012), who solved the crystal structure of the agonist-bound receptor, and refined further by Deluigi and colleagues (Science Advances, 2021), whose structures of NTSR1 bound to small-molecule agonists, partial agonists, and inverse agonists revealed the determinants of full versus partial receptor activation.
What it does
Neuromedin N binds and activates NTSR1 — a class A G protein-coupled receptor (GPCR) expressed broadly in the central nervous system, gut, and peripheral vasculature. Through this receptor it participates in dopamine modulation, pain signaling, and cardiovascular regulation. In dopamine-rich brain circuits, activation of NTSR1 by neuromedin N affects dopamine neuron activity in a region-specific way. In the cardiovascular system, stimulation of this receptor pathway influences vascular tone and blood pressure, as reviewed by Osadchii (European Journal of Pharmacology, 2015). The C-terminal four residues shared between neuromedin N and the active core of neurotensin — Pro-Tyr-Ile-Leu — are responsible for receptor binding, consistent with structure-activity data showing that the C-terminal hexapeptide of neurotensin contains all the determinants needed for NTSR1 activation (Besserer-Offroy et al., European Journal of Pharmacology, 2017).
Evidence
- Human: No clinical trials are registered for neuromedin N as a standalone intervention. The precursor protein pro-NT/NMN circulates in plasma and has been studied as a biomarker: elevated levels of the stable pro-peptide have been associated prospectively with cardiovascular risk and metabolic parameters in epidemiological cohorts (not directly applicable to neuromedin N administration, but consistent with the relevance of this peptide system in human physiology).
- Animal: In rodent studies, neuromedin N injected into the ventral tegmental area modulated dopamine metabolism in downstream projection areas (nucleus accumbens, prefrontal cortex, diagonal band of Broca, septum) and affected motor activity, with a distinct potency profile relative to neurotensin. No analgesic or hypothermic effect was observed with intracerebroventricular neuromedin N administration in rodent paradigms that are sensitive to full-length neurotensin, indicating functional differences between the two co-released peptides.
- In vitro: Besserer-Offroy and colleagues (2017) characterized the signaling signature of NTSR1 with endogenous ligands including neuromedin N: it activates Gαq-, Gαi1-, GαoA-, and Gα13-protein pathways as well as recruiting β-arrestins 1 and 2, mirroring the full signaling engagement seen with neurotensin and the minimal fragment neurotensin (8-13). Neuromedin N was more rapidly inactivated by brain synaptic peptidases than neurotensin itself, with aminopeptidase and metallopeptidase activities responsible for its degradation; the primary degradation product (neuromedin N residues 2–6) was shown to lack receptor binding activity.
Mechanism
Neuromedin N is the C-terminal hexapeptide of the pro-NT/NMN precursor; its sequence KIPYIL mirrors the C-terminus of neurotensin (positions 8–13: RRPYIL), which constitutes the pharmacophoric core of the entire neurotensin peptide family. Upon binding NTSR1, it engages a coupling profile spanning Gαq, Gαi1, GαoA, and Gα13, as well as β-arrestin-1 and β-arrestin-2 recruitment (Besserer-Offroy et al. 2017). The distinct signaling outcomes downstream of G protein versus β-arrestin arms of NTSR1 have become an area of active investigation for pain and addiction pharmacology, though this work has focused primarily on neurotensin and synthetic analogs rather than neuromedin N specifically. Structural studies by White and colleagues (Nature, 2012) and Deluigi and colleagues (Science Advances, 2021) have defined the binding pocket architecture and the conformational differences that distinguish full agonism, partial agonism, and inverse agonism at NTSR1 — a receptor that also mediates the oncological relevance of this peptide family, as NTSR1 is overexpressed in pancreatic ductal adenocarcinoma and several other tumor types, making it a target of interest for cancer imaging and therapy (Kitabgi 2006; Deluigi et al. 2021).
Differential processing of the shared precursor is itself biologically significant: Kitabgi (2006) showed that PC2 preferentially generates neuromedin N over neurotensin in certain tissues, producing a local peptide environment enriched in the shorter ligand. Because neuromedin N is degraded faster than neurotensin by synaptic peptidases, its half-life and sphere of action are more restricted — suggesting the two co-released peptides may have distinct spatial and temporal signaling roles at the same receptor despite overlapping pharmacology.
Known effects
- NTSR1 agonism — Mechanistic only; established in vitro (Besserer-Offroy et al. 2017)
- Dopamine system modulation — Preclinical (rodent VTA/nucleus accumbens studies)
- Cardiovascular signaling (vasodilation, blood pressure effects) — Preclinical; receptor-level evidence (Osadchii 2015)
- Smooth muscle contraction (guinea pig ileum) — Bioassay evidence from original isolation (Minamino et al. 1984)
Regulatory status
- US: No FDA-approved therapeutic use. Research reagent only.
- EU: No EMA approval. Research use only.
- Clinical trials: No registered trials on ClinicalTrials.gov for neuromedin N as a therapeutic agent.
Related peptides
Neuromedin N is the shorter co-product of the pro-neurotensin/neuromedin N precursor. Its closest functional relatives on the platform:
- Neurotensin — the 13-residue parent neuropeptide co-encoded in the same precursor gene; both peptides activate NTSR1, but neurotensin has greater receptor binding affinity and is more resistant to synaptic peptidase degradation.
- Neurotensin (8-13) — the minimal NTSR1 pharmacophore derived from the C-terminus of neurotensin; its six-residue sequence overlaps with the C-terminal four residues of neuromedin N, making it the closest structural analog of neuromedin N in the neurotensin fragment series.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does the relative amount of neuromedin N versus neurotensin released from neurons act as a built-in dimmer switch for neurotensin receptor activity?
If confirmed, it would reveal a new layer of brain signal control, and diseases involving abnormal processing enzymes, such as obesity or certain cancers, could be re-understood as disorders of this ratio, potentially leading to new treatment angles.
Could neuromedin N contact the neurotensin receptor in a subtly different way than neurotensin, leading to different downstream signals?
If this difference exists, neuromedin N could become a starting point for drugs that lean toward particular neurotensin-receptor pathways, such as those tied to pain or appetite, though whether the binding really differs and what signals follow would still need to be shown.
Does the proline at position three of neuromedin N help shape the peptide so its receptor-binding end is presented correctly?
If it does, drug designers could try to lock neuromedin N into its active shape with constrained analogs, which might yield more potent and stable candidates, though the exact role of the proline still needs testing.
Can neuromedin N be chemically modified at its open end to add delivery or stability features without losing receptor binding?
If it can, neuromedin N could serve as a compact, modifiable scaffold for receptor-targeting molecules, though whether such tags actually improve brain delivery or persistence would still need to be demonstrated, especially since the bare peptide is broken down quickly in the body.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9659630060195923 | boltz-2 |
| ranking score | 0.7956021428108215 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.841 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10610,
sequence = {KIPYIL},
target = {ntsr1},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}